Abstract: The present disclosure provides an N protein epitope mutation marker for preparing an epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof, belonging to the technical field of biological products. In the mutation marker, one or more amino acids are mutated based on an epitope sequence at positions 92 to 103 of a C-terminal of an N protein of the type II PRRSV; and the epitope mutation marker has an amino acid sequence shown in SEQ ID NO: 1, where X1 is selected from the group consisting of T, P, and A; and X2 is selected from the group consisting of V and A.

Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessels. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

Abstract: PLXDC1 and PLXDC2 represent a new cell-surface receptor family (collectively referred to as PLXDC proteins). The present disclosure reports that Domain A of the PLXDC proteins functions as an inhibitory domain, as the deletion thereof activates PLXDC signaling. Antibodies and antigen-binding fragments that bind to Domain A can therefore relieve its inhibitory function and activate PLXDC signaling, leading to killing of endothelial cells in pathogenic blood vessel that express the PLXDC protein. Methods are described for efficient screening of PLXDC-activating antibodies that bind to Domain A. In particular, the method entails the use of a small molecule agent that binds the PLXDC protein, making Domain A more accessible to a test antibody. With the new method, antibodies that bind to Domain A and can activate PLXDC signaling have been successfully identified.

Abstract: Pathogenic blood vessels are blood vessels that are not involved in the vascularization of normal organs but are in the pathogenic tissues such as the new blood vessels that drive vision diseases or the blood vessels in tumors that tumors depend on to survive. The current disclosure provides an advancement over typical anti-angiogenic strategies that target the generation of new blood vessels by providing compositions and methods that can selectively target and kill existing pathogenic blood vessels. The conventional antiangiogenic drugs or factors inhibit angiogenesis (the growth of new blood vessels), but cannot effectively kill existing pathogenic blood vessels. Agents, including small molecule compounds and antibodies, have been identified that bind to and activate PLXDC1 and PLXDC2 proteins, leading to effective killing of the endothelial cells in pathogenic blood vessels in vision diseases and in tumors that express these proteins.

Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessels. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

Abstract: The present disclosure provides an N protein epitope mutation marker for preparing an epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof, belonging to the technical field of biological products. In the mutation marker, one or more amino acids are mutated based on an epitope sequence at positions 92 to 103 of a C-terminal of an N protein of the type II PRRSV; and the epitope mutation marker has an amino acid sequence shown in SEQ ID NO: 1, where X1 is selected from the group consisting of T, P, and A; and X2 is selected from the group consisting of V and A.

Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

Abstract: The present invention provides a two-step auto-injection apparatus consisting of a housing, a protective sleeve cylinder, a pre-filled injection assembly and a drive feedback apparatus, wherein the pre-filled injection assembly is loaded into the housing, and the protective sleeve cylinder covers a needle of the pre-filled injection assembly, so that the protective sleeve cylinder directly contacts an injecting portion and the function of injection can be realized by pressing to trigger the drive feedback apparatus during use, thereby facilitating quick operation with a needle tip hidden in the whole process; the drive feedback apparatus of a piston in a needle cylinder is driven to combine a release mechanism with an ejection mechanism and a feedback mechanism, and the release mechanism is triggered by pressing the protective sleeve cylinder, so that the ejection mechanism is released, and the ejection mechanism interacts with the feedback mechanism in a form of collision, for example, to generate a sound si

Abstract: A mask strip, comprising: a plurality of mask units (2) in a first direction; each of the mask units (2) comprising a mask region (3) and a non-mask region (11) surrounding the mask region (3), the non-mask region (11) comprising a side region (4) and an original stress concentration region (6) inside the side region (4); each of the mask units (2) further comprising a stress concentration structure, wherein the stress concentration structure is within a part of the side region (4) other than the original stress concentration region (6). Also discloses a mask plate and a method of fabricating a mask strip.

Abstract: The present disclosure provides a mask tension frame and a mask tension process, where the mask tension frame includes a frame body and a supporting rib. The frame body is provided with a first surface, a second surface, and an opening. The first surface and the second surface are oppositely disposed, and the opening is recessed in the direction from the first surface toward the second surface. The supporting rib spans the opening of the frame body. A surface of the supporting rib for supporting the mask is higher than the first surface with respect to the second surface. When the mask is being tensed by the mask tension frame, at least a portion of the mask is supported by the supporting rib and at least a portion of the mask adjacent to an edge of the mask is supported by the first surface.

Abstract: A mask assembly and a method of patterning a semiconductor film using the mask assembly. A first mask comprises a plurality of first light shielding regions, a plurality of first light transmissive regions, and at least one first light shielding island; a boundary of a first light shielding island is not connected to a boundary of the first mask; a second mask comprises a plurality of second light shielding regions, a plurality of second light transmissive regions, and at least one second light shielding island; a boundary of the second light shielding island is not connected to a boundary of the second mask; the first light shielding region and the second light shielding region are complementarily arranged, the first light transmissive region and the second light transmissive region are complementarily disposed.

Abstract: A mask assembly and a method of patterning a semiconductor film using the mask assembly. A first mask comprises a plurality of first light shielding regions, a plurality of first light transmissive regions, and at least one first light shielding island; a boundary of a first light shielding island is not connected to a boundary of the first mask; a second mask comprises a plurality of second light shielding regions, a plurality of second light transmissive regions, and at least one second light shielding island; a boundary of the second light shielding island is not connected to a boundary of the second mask; the first light shielding region and the second light shielding region are complementarily arranged, the first light transmissive region and the second light transmissive region are complementarily disposed.

Abstract: The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

Abstract: Pathogenic blood vessels are blood vessels that are not involved in the vascularization of normal organs but are in the pathogenic tissues such as the new blood vessels that drive vision diseases or the blood vessels in tumors that tumors depend on to survive. The current disclosure provides an advancement over typical anti-angiogenic strategies that target the generation of new blood vessels by providing compositions and methods that can selectively target and kill existing pathogenic blood vessels. The conventional antiangiogenic drugs or factors inhibit angiogenesis (the growth of new blood vessels), but cannot effectively kill existing pathogenic blood vessels. Agents, including small molecule compounds and antibodies, have been identified that bind to and activate PLXDC1 and PLXDC2 proteins, leading to effective killing of the endothelial cells in pathogenic blood vessels in vision diseases and in tumors that express these proteins.

Abstract: This disclosure relates to the field of display fabrication technologies, and discloses a fine mask support frame, a fine mask, and a method for fabricating the same. The fine mask support frame includes: a plurality of bezels surrounding a mask area, wherein adjustment openings are arranged on at least one pair of bezels arranged opposite to each other, and at least one adjustment piece is arranged on each of the adjustment openings, wherein the adjustment piece is configured to adjust a shape of a corresponding adjustment opening to thereby adjust deformation of the mask area.

Abstract: The present invention relates to a method for preparing a whole bovine-derived broadly neutralizing antibody against serotype O foot-and-mouth disease virus, and belongs to the technical field of antibody preparation. The method includes the following steps: 1) conducting the immunization on the cattle; 2) screening for the serotype O foot-and-mouth disease virus antigen-specific single B cells; 3) amplifying variable region genes of the heavy and light chains; 4) acquiring constant region sequences of the heavy and light chains; 5) preparing a full-length heavy chain vector; 6) co-transfecting a cell, taking the supernatant of cell culture, and purifying. The method utilizes different foot-and-mouth disease virus strains to infect cattle and obtains a neutralizing antibody capable of neutralizing three topotypes of serotype O FMDVs by screening, and thus can obtain a whole bovine-derived broadly neutralizing monoclonal antibody.

Abstract: The present invention relates to a method for preparing a whole bovine-derived broadly neutralizing antibody against serotype O foot-and-mouth disease virus, and belongs to the technical field of antibody preparation.

Abstract: This disclosure relates to the field of display fabrication technologies, and discloses a fine mask support frame, a fine mask, and a method for fabricating the same so as to improve the positional precision of opening areas of the mask to thereby further improve the precision of the mask. The fine mask support frame includes: a plurality of bezels surrounding a mask area, wherein adjustment openings are arranged on at least one pair of bezels arranged opposite to each other, and at least one adjustment piece is arranged on each of the adjustment openings, wherein the adjustment piece is configured to adjust a shape of a corresponding adjustment opening to thereby adjust deformation of the mask area.

Abstract: An engine control system includes a selective catalyst reduction (SCR) device that reduces nitrogen oxide (NOx) in exhaust gas in the presence of the reductant. A particulate filter (PF) is disposed downstream from the SCR device to collect particulate matter from the exhaust gas stream. The engine control system further includes an electronic hardware that calculates a particulate matter load value indicating an amount of particulate matter collected in the PF, and calculate a CCB value that compensates for pressure differential variations across the PF. The controller further calculates a CCB correction value that modifies the CCB value and compensates for an amount of reductant that slips from the SCR device and induces the pressure differential variations. In this manner, the electronic hardware controller can control a regeneration system to increase the temperature of the PF to burn off particulate matter from the PF based on the modified CCB value.

Abstract: An engine control system includes a selective catalyst reduction (SCR) device that reduces nitrogen oxide (NOx) in exhaust gas in the presence of the reductant. A particulate filter (PF) is disposed downstream from the SCR device to collect particulate matter from the exhaust gas stream. The engine control system further includes an electronic hardware that calculates a particulate matter load value indicating an amount of particulate matter collected in the PF, and calculate a CCB value that compensates for pressure differential variations across the PF. The controller further calculates a CCB correction value that modifies the CCB value and compensates for an amount of reductant that slips from the SCR device and induces the pressure differential variations. In this manner, the electronic hardware controller can control a regeneration system to increase the temperature of the PF to burn off particulate matter from the PF based on the modified CCB value.